Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 08:00 ET | Source: Remix Therapeutics

Remix Therapeutics to Present at Guggenheim Second Annual Healthcare Innovation Conference

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
October 24, 2025 10:00 ET | Source: Remix Therapeutics

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Preliminary Results Yield 43% Overall Response Rates (via RECIST) in the Efficacy Population Data Demonstrate REM-422, the First-in-Class Small Molecule MYB mRNA Degrader, Reduces Expression of the...
October 13, 2025 12:49 ET | Source: Remix Therapeutics

Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation

WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
April 15, 2025 07:00 ET | Source: Remix Therapeutics

Remix Therapeutics Appoints Linda C. Bain to Board of Directors

WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
March 31, 2025 07:00 ET | Source: Remix Therapeutics

Remix Therapeutics to Present at Stifel 2025 Virtual Targeted Oncology Forum

WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
February 27, 2025 07:00 ET | Source: Remix Therapeutics

Remix Therapeutics Announces Participation in Leerink Global Healthcare Conference

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
December 08, 2022 08:00 ET | Source: Remix Therapeutics

Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit

CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying...
December 15, 2021 08:00 ET | Source: Remix Therapeutics

Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying...
December 06, 2021 08:00 ET | Source: Remix Therapeutics

Remix Therapeutics to Present at 4th Annual RNA-Targeted Drug Discovery Summit

CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying...